Holen Sie sich die Stockscreener-App
1.765
4.44%
0.075
Schlusskurs vom Vortag:
$1.69
Offen:
$1.72
24-Stunden-Volumen:
581.20K
Relative Volume:
0.65
Marktkapitalisierung:
$159.42M
Einnahmen:
$70.14M
Nettoeinkommen (Verlust:
$-76.24M
KGV:
-1.5901
EPS:
-1.11
Netto-Cashflow:
$-57.06M
1W Leistung:
+1.44%
1M Leistung:
-18.66%
6M Leistung:
-24.25%
1J Leistung:
-63.91%
1-Tages-Spanne:
$1.665
$1.77
1-Wochen-Bereich:
$1.62
$1.79
52-Wochen-Spanne:
$1.52
$6.08
Codexis Inc Stock (CDXS) Company Profile
Firmenname
Codexis Inc
Sektor
Branche
Telefon
650-421-8100
Adresse
200 PENOBSCOT DRIVE, REDWOOD CITY, CA
Vergleichen Sie CDXS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CDXS
Codexis Inc
|
1.765 | 152.65M | 70.14M | -76.24M | -57.06M | -1.11 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.26 | 117.50B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
722.83 | 76.06B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.56 | 62.53B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
916.31 | 56.75B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
205.04 | 44.10B | 447.02M | -1.18B | -906.14M | -6.1812 |
Codexis Inc Stock (CDXS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-08-19 | Herabstufung | The Benchmark Company | Buy → Hold |
| 2024-06-03 | Fortgesetzt | Jefferies | Buy |
| 2024-05-30 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-02-29 | Hochstufung | The Benchmark Company | Hold → Buy |
| 2023-11-07 | Herabstufung | The Benchmark Company | Buy → Hold |
| 2023-08-07 | Herabstufung | TD Cowen | Outperform → Market Perform |
| 2023-05-09 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2022-03-31 | Fortgesetzt | Piper Sandler | Overweight |
| 2022-03-02 | Fortgesetzt | Cowen | Outperform |
| 2021-04-12 | Eingeleitet | Piper Sandler | Overweight |
| 2021-03-01 | Eingeleitet | Stifel | Buy |
| 2021-02-26 | Bestätigt | H.C. Wainwright | Buy |
| 2020-03-10 | Eingeleitet | The Benchmark Company | Buy |
| 2019-01-17 | Hochstufung | First Analysis Sec | Neutral → Outperform |
| 2018-05-16 | Eingeleitet | Stephens | Overweight |
| 2017-10-13 | Bestätigt | H.C. Wainwright | Buy |
| 2017-05-31 | Eingeleitet | Jefferies | Buy |
| 2017-01-26 | Herabstufung | First Analysis Sec | Overweight → Equal-Weight |
| 2017-01-04 | Hochstufung | Ladenburg Thalmann | Neutral → Buy |
| 2016-01-06 | Eingeleitet | H.C. Wainwright | Buy |
Alle ansehen
Codexis Inc Aktie (CDXS) Neueste Nachrichten
Will Codexis Inc. stock benefit from upcoming earnings reportsMarket Risk Summary & Entry Point Confirmation Alerts - Newser
Codexis' ECO Synthesis® Manufacturing Platform: Transforming RNA Therapeutics - CBS News
Opaleye Management Inc. Reduces Stake in Codexis Inc. - GuruFocus
Is Codexis Inc. stock supported by strong fundamentals2025 Investor Takeaways & Risk Managed Trade Strategies - Newser
Enzyme Engineering Market is Going to Boom: Strategic Insights - openPR.com
A Look at Codexis Inc (CDXS) Shares in the Recent Past Indicates Growth - Setenews
Major Shareholder Sells Off a Chunk of Codexis Stock! - TipRanks
Codexis (CDXS) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
Operating cash flow per share of Codexis, Inc. – DUS:4QK - TradingView
Owner Opaleye Management Inc Sells 514,341 ($877.8K) Of Codexis Inc [CDXS] - TradingView
Trading Recap: Is Codexis Inc. stock vulnerable to regulatory risksJuly 2025 Snapshot & Weekly Setup with High ROI Potential - BỘ NỘI VỤ
[Form 4] CODEXIS, INC. Insider Trading Activity - Stock Titan
Check out these key findings about Codexis Inc (CDXS) - Setenews
Codexis Inc (CDXS) Stock Forecast, Price Targets and Analysts Predictions - GuruFocus
Telemark Asset Management LLC Increases Stock Position in Codexis, Inc. $CDXS - MarketBeat
Dir Wolf Files To Sell 8,952 Of Codexis Inc [CDXS] - TradingView
Can Codexis Inc. stock beat market expectations this quarter2025 Macro Impact & Weekly Watchlist for Consistent Profits - newser.com
Codexis strengthens board with biotech veteran Arthur Levin - MSN
Is Codexis Inc. stock attractive for ETFsTrade Analysis Summary & Daily Profit Maximizing Tips - newser.com
Will Codexis Inc. stock outperform tech sector in 2025Quarterly Profit Report & Risk Managed Investment Entry Signals - newser.com
Will Codexis Inc. stock sustain high P E ratiosJuly 2025 Spike Watch & Risk Controlled Daily Trade Plans - newser.com
Why Codexis Inc. stock is considered a top pickJuly 2025 Summary & Risk Controlled Daily Plans - newser.com
Strategies to average down on Codexis Inc.July 2025 Fed Impact & Weekly Setup with ROI Potential - newser.com
Is Codexis Inc. stock dividend yield sustainableJuly 2025 Update & Weekly Stock Breakout Alerts - newser.com
How to escape a deep drawdown in Codexis Inc.July 2025 News Drivers & Risk Managed Investment Strategies - newser.com
Will Codexis Inc. stock deliver long term returnsJuly 2025 Sector Moves & Reliable Entry Point Alerts - newser.com
An analyst sees good growth prospects for Codexis Inc (CDXS) - Setenews
Will Codexis Inc. price bounce be sustainableJuly 2025 PreEarnings & Long-Term Capital Growth Strategies - newser.com
Jeff Bluestone to step down as CEO of Sonoma BiotherapeuticsSan Francisco Business Times - The Business Journals
Sonoma Biotherapeutics Names Stephen Dilly as CEO - Contract Pharma
Sonoma Biotherapeutics Announces Transition of Jeff Bluestone, PhD, to Advisor; Appoints Stephen Dilly, MBBS, PhD, as President and Chief Executive Officer - Business Wire
Can volume confirm reversal in Codexis Inc.Weekly Trade Analysis & Proven Capital Preservation Tips - newser.com
What risks investors should watch in Codexis Inc. stock2025 Institutional Moves & Short-Term Trading Alerts - newser.com
How Codexis Inc. stock reacts to oil pricesJuly 2025 Sector Moves & Weekly Chart Analysis and Trade Guides - newser.com
Major Shareholder Offloads Massive Codexis Stock! - TipRanks
Is Codexis Inc. meeting your algorithmic filter criteria2025 Analyst Calls & Verified Entry Point Detection - newser.com
Finanzdaten der Codexis Inc-Aktie (CDXS)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.10%
1.10%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):